FDA has issued a draft guidance titled “Establishing Impurity Specifications for Antibiotics” for the pharmaceutical industry. The document provides recommendations for setting impurity specifications for antibiotics produced through fermentation or semi synthesis.
The guidance aims to provide a clearer framework for impurity control and quality oversight throughout the manufacturing process. The public consultation period will remain open until June 22, 2026 allowing stakeholders to submit comments by that date.